Clinical Trials Logo

Exendin (9-39) clinical trials

View clinical trials related to Exendin (9-39).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00468091 Completed - Clinical trials for Gastrointestinal Motility

Effects of Exendin(9-39) on Gastroduodenal Motility

Start date: February 1999
Phase: Phase 1
Study type: Interventional

The purpose of this study in humans is to define the effects of the endogenous hormone GLP-1 on gastroduodenal motility and on endocrine pancreatic secretion by using the specific GLP-1 receptor antagonist exendin(9-39). To elucidate possible cholinergic pathways, we combined exendin(9-39) with the muscarinergic antagonist atropine.